Annamycin liposomal - Moleculin Biotech
Alternative Names: Annamycin-LF; Annamycin-liposomal; L-ANNA; L-annamycin; Liposomal annamycin; S-ANNALatest Information Update: 22 Aug 2024
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer Aronex Pharmaceuticals; Callisto Pharmaceuticals; Moleculin Biotech; University of Texas M. D. Anderson Cancer Center
- Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Small molecules
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Soft tissue sarcoma
- Phase I/II Acute myeloid leukaemia
- Preclinical Colorectal cancer; Liver cancer; Pancreatic cancer; Solid tumours
- Discontinued Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Triple negative breast cancer
Most Recent Events
- 14 Aug 2024 Updated efficacy and adverse events data from a phase I/II trial in Acute myeloid leukaemia released by Moleculin Biotech
- 05 Aug 2024 Moleculin Biotech plans a phase III MIRACLE trial for Acute myeloid leukaemia (Second-line therapy or greater, combination therapy) worldwide in Q1 2025
- 01 Aug 2024 Moleculin Biotech intends to amend current investigational new drug application